MSH2 and neoplasm: Contrary to the results of the MLH1 immunohistochemistry, MSH2 expression loss was similarly infrequent both in MSI+ tumours and in those with stable microsatellites and, consequently, not associated with the MSI+ phenotype (data not shown).